Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.
Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States. The company operates manufacturing facilities across the Middle East and North Africa region, Europe and North America, supporting a global supply chain for both sterile and non-sterile products. Hikma’s international footprint is complemented by localized sales and distribution networks, enabling tailored product offerings and regulatory compliance in more than 50 markets.
Hikma places strong emphasis on research and development, with dedicated R&D centers focused on formulation development and process engineering for both generic and injectable medicines. The company’s leadership team, guided by a board of directors with extensive industry experience, drives a strategic vision centered on delivering high-quality medicines, expanding into new markets and pursuing innovative partnerships. Corporate governance and sustainability initiatives underpin Hikma’s commitment to patient access, ethical practices and long-term value creation for stakeholders.
AI Generated. May Contain Errors.
Free HKMPF Stock Alerts